But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...

The stock has also performed well this year, rising roughly 36% (as of Nov. 14), ahead of the broader market. Given that Eli ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...

Lee Munson, president and CIO at Portfolio Wealth Advisors, joins CNBC’s ‘Power Lunch’ to discuss outlooks on three stocks: ...

Eli Lilly (LLY) has filed a lawsuit against the heads of the Department of Health and Human Services and one of its agencies, seeking a court ...

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...

Conditions are getting a bit more challenging for the drugmaker.

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong ...

Nov 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results ...